| Chronic oxidative stress induces a tissue-specific reduction in telomere length in CAST/Ei mice V Cattan, N Mercier, JP Gardner, V Regnault, C Labat, J Mäki-Jouppila, ... Free Radical Biology and Medicine 44 (8), 1592-1598, 2008 | 121 | 2008 |
| Hydroxysteroid (17β) dehydrogenase 13 deficiency triggers hepatic steatosis and inflammation in mice M Adam, H Heikelae, C Sobolewski, D Portius, J Mäki-Jouppila, ... The FASEB Journal 32 (6), 3434-3447, 2018 | 69 | 2018 |
| The hydroxysteroid (17β) dehydrogenase family gene HSD17B12 is involved in the prostaglandin synthesis pathway, the ovarian function, and regulation of fertility H Kemiläinen, M Adam, J Mäki-Jouppila, P Damdimopoulou, ... Endocrinology 157 (10), 3719-3730, 2016 | 55 | 2016 |
| Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells’ sensitivity to paclitaxel M Tambe, S Pruikkonen, J Mäki-Jouppila, P Chen, BV Elgaaen, ... Oncotarget 7 (11), 12267, 2016 | 41 | 2016 |
| Excess of miRNA-378a-5p perturbs mitotic fidelity and correlates with breast cancer tumourigenesis in vivo S Winsel, J Mäki-Jouppila, M Tambe, MR Aure, S Pruikkonen, AL Salmela, ... British journal of cancer 111 (11), 2142-2151, 2014 | 30 | 2014 |
| The flavonoid eupatorin inactivates the mitotic checkpoint leading to polyploidy and apoptosis AL Salmela, J Pouwels, A Kukkonen-Macchi, S Waris, P Toivonen, ... Experimental Cell Research 318 (5), 578-592, 2012 | 30 | 2012 |
| MicroRNA let-7b regulates genomic balance by targeting Aurora B kinase JHE Mäki-Jouppila, S Pruikkonen, MB Tambe, MR Aure, T Halonen, ... Molecular oncology 9 (6), 1056-1070, 2015 | 25 | 2015 |
| Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer M Knuuttila, A Mehmood, J Mäki-Jouppila, H Ryberg, P Taimen, ... Endocrine-related cancer 25 (9), 807-819, 2018 | 21 | 2018 |
| Centmitor-1, a novel acridinyl-acetohydrazide, possesses similar molecular interaction field and antimitotic cellular phenotype as rigosertib, on 01910. Na JHE Mäki-Jouppila, LJ Laine, J Rehnberg, E Narvi, P Tiikkainen, ... Molecular cancer therapeutics 13 (5), 1054-1066, 2014 | 10 | 2014 |
| Human immune system increases breast cancer-induced osteoblastic bone growth in a humanized mouse model without affecting normal bone TE Kähkönen, MI Suominen, JHE Mäki-Jouppila, JM Halleen, A Tanaka, ... Journal of Immunology Research 2019, 2019 | 9 | 2019 |
| Novel pyrimidine-2, 4-diamine derivative suppresses the cell viability and spindle assembly checkpoint activity by targeting Aurora kinases AL Salmela, J Pouwels, J Mäki-Jouppila, P Kohonen, P Toivonen, L Kallio, ... Carcinogenesis 34 (2), 436-445, 2013 | 7 | 2013 |
| Additive benefits of radium-223 dichloride and bortezomib combination in a systemic multiple myeloma mouse model MI Suominen, J Mäki-Jouppila, A Huhtinen, B Sjöholm, JP Rissanen, ... International Journal of Molecular Sciences 22 (11), 5570, 2021 | 5 | 2021 |
| Abstract LB-A01: Establishment of a novel prostate cancer bone metastasis model in humanized mice and early efficacy results of pembrolizumab TE Kähkönen, MI Suominen, JHE Mäki-Jouppila, A Tanaka, P Dube, ... Molecular Cancer Therapeutics 18 (12_Supplement), LB-A01-LB-A01, 2019 | 3 | 2019 |
| VTT-006, an anti-mitotic compound, binds to the Ndc80 complex and suppresses cancer cell growth in vitro LJ Laine, JHE Mäki-Jouppila, E Kutvonen, P Tiikkainen, TKM Nyholm, ... Oncoscience 8, 134, 2021 | 2 | 2021 |
| Efficacy of anti-PD-1, IDO inhibitor, chemotherapy and bone-targeting agent on tumor growth in a syngeneic bone metastasis model of triple-negative breast cancer TE Kähkönen, MI Suominen, JH Mäki-Jouppila, JM Halleen, J Bernoulli Cancer Research 80 (16_Supplement), 5026-5026, 2020 | 2 | 2020 |
| Immune cell killing assay for measuring the effects of immunomodulating agents in lung cancer cells in vitro JH Mäki-Jouppila, JP Rissanen, KM Fagerlund Cancer Research 82 (12_Supplement), 1624-1624, 2022 | 1 | 2022 |
| Systemic and local bone metastasis models for immuno-oncology drug development TE Kähkönen, MI Suominen, JH Mäki-Jouppila, JM Halleen, A Scholz, ... Cancer Research 79 (13_Supplement), 2814-2814, 2019 | 1 | 2019 |
| Drug sensitivity profiling of BT-474 breast cancer cell line for identification of novel therapies targeting HER2-positive breast cancer JH Mäki-Jouppila, TE Kähkönen, MI Suominen, JM Halleen, J Bernoulli, ... Cancer Research 78 (13_Supplement), 2684-2684, 2018 | 1 | 2018 |
| Importance of tumor microenvironment in the preclinical estrogen receptor positive breast cancer-primary tumor and bone metastasis models J Bernoulli, MI Suominen, T Kähkönen, J Mäki-Jouppila, JM Halleen, ... Cancer Research 77 (13_Supplement), 4968-4968, 2017 | 1 | 2017 |
| Selective drug sensitivity score (DSS) for indolent and aggressive prostate cancer cell lines J Mäki-Jouppila, J Bernoulli, J Tuomela, MI Suominen, JM Halleen, ... Cancer Research 77 (13_Supplement), 4207-4207, 2017 | 1 | 2017 |
